干细胞样CD8^(+)T细胞在抗肿瘤免疫治疗中的地位与演进效应

Role and mechanism of action of stem-like CD8^(+)T cells in anti-tumor immunotherapy

以抗细胞程序性死亡-1/细胞程序性死亡-配体1(programmed cell death-1/programmed cell death-ligand 1,PD-1/PD-L1)为代表的免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗显现了CD8+T细胞在治疗和可能治愈恶性肿瘤方面的潜力。但仅约20%的患者对ICIs治疗获益,因此阐明CD8+T细胞在免疫微环境中的有效抗肿瘤功能,及其分子和空间的决定因素尤为重要。具有自我更新、增殖分化和杀伤肿瘤细胞能力的干细胞样CD8^(+)T细胞亚群,在介导抗肿瘤免疫效应方面扮演极为重要的角色。本文就干细胞样CD8^(+)T细胞在抗肿瘤免疫循环中的地位与演进效应进行综述。

Anti-programmed cell death-1/programmed cell death-ligand 1(PD-1/PD-L1)as immune checkpoint inhibitors(ICIs)therapy has shown the potential of CD8+T cells in treating and possibly curing malignancies.However,only approximately 20%of patients benefit from ICI therapy.Therefore,it is necessary to elucidate the antitumor function of CD8+T cells in the immune microenvironment and its molecular and spatial mechanism of action.Stem-like CD8^(+)T-cell subsets with the ability of self-renewal,proliferation,differentiation,and killing of tumor cells play a vital role in mediating anti-tumor effects.In this review,we analyzed the roles and evolutionary effects of stem-like CD8^(+)T cells in anti-tumor effects.